GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Other Long-Term Liabilities

Xbrane Biopharma AB (STU:7XB) Other Long-Term Liabilities : €-0.00 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Other Long-Term Liabilities?

Xbrane Biopharma AB's other long-term liabilities for the quarter that ended in Sep. 2024 was €-0.00 Mil.

Xbrane Biopharma AB's quarterly other long-term liabilities increased from Mar. 2024 (€-0.00 Mil) to Jun. 2024 (€0.00 Mil) but then declined from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€-0.00 Mil).

Xbrane Biopharma AB's annual other long-term liabilities declined from Dec. 2021 (€0.05 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Xbrane Biopharma AB Other Long-Term Liabilities Historical Data

The historical data trend for Xbrane Biopharma AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Other Long-Term Liabilities Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Xbrane Biopharma AB Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Other Long-Term Liabilities
Comparable Companies
OSTO:DMYD B OSTO:CANTA XSAT:CURAS OSTO:ONCO OSTO:SYNACT OSTO:ITECH OSTO:INIT OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XBRANE:Sweden
Address
Retzius vag 8, Solna, SWE, 171 65
Website
https://www.xbrane.com
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.

Xbrane Biopharma AB Headlines

No Headlines